Research Article

Total Saponins from Nigella glandulifera Seeds Ameliorate Adjuvant-Induced Rheumatoid Arthritis in Rats by Inhibition of an Inflammatory Response and Bone Erosion

Li Zeng,1 Chenyang Li,2 Hailun Jiang,1 Yan Chen,2 Zhuorong Li,1 Fang Xu,2 and Rui Liu1

1Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
2Key Laboratory of Uighur Medicine of Xinjiang Uygur Autonomous Region, Xinjiang Institute of Materia Medica, Urumqi 830004, China

Correspondence should be addressed to Fang Xu; xufangxj@163.com and Rui Liu; liurui@imb.pumc.edu.cn

Received 4 November 2020; Revised 9 January 2021; Accepted 13 January 2021; Published 29 January 2021

Academic Editor: Atef M. Al Attar

Copyright © 2021 Li Zeng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Rheumatoid arthritis (RA) is a widespread inflammatory disease whose clinical manifestations are joint swelling, pain, and disability, affecting approximately 1% of individuals worldwide. Conventional anti-RA drugs currently used in clinic have severe side effects. The present study is aimed at investigating the antiarthritic effects of total saponins from Nigella glandulifera seeds (TSNGS) in rats with adjuvant-induced rheumatoid arthritis (AIA). Arthritis score, paw swelling, and body weight were monitored throughout the period of TSNGS treatment. The histopathological features and levels of cytokines, including IFN-γ, TNF-α, IL-1β, IL-4, IL-6, IL-10, and IL-17A, and OPG/RANKL signaling, were measured to determine the amelioration by TSNGS and its potential mechanisms on the inflammatory response and bone erosion. The differentiation of regulatory T cells (Tregs) in serum was assessed by flow cytometry. The results demonstrate that TSNGS at 10 mg/kg, 50 mg/kg, and 250 mg/kg inhibited AIA-induced clinical score, paw swelling, and histological changes. TSNGS reduced the immune-inflammatory reaction by restoring the secretion and expression of inflammatory cytokines and elevating the proportion of CD4+ CD25+ Tregs, accompanied by an increase in transcription factor Foxp3 levels. TSNGS also displayed bone protection by upregulation of the OPG/RANKL pathway. Collectively, TSNGS inhibited arthritis in AIA rats and so represents a potential novel treatment for RA.

1. Introduction

Rheumatoid arthritis (RA) is a chronic and progressive autoimmune disease of unknown etiology, characterized by synovial inflammation and hyperplasia, the formation of pannus, and cartilage destruction that result in irreversible joint damage and severe disability [1]. It has been reported that the prevalence of RA is between 0.4% and 1.2%, while the incidence in women is almost 2-4-fold greater than in males [2, 3]. The focus of treatment given to RA patients is currently immune suppression plus nonsteroidal anti-inflammatory drugs (NSAIDs) and disease-modifying antirheumatic drugs (DMARDs) to relieve their immuno-inflammatory response and the pain symptoms of RA, including Tripterygium wilfordii polyglycosides, methotrexate, and glucocorticoids. Long-term use leads to serious side effects on the kidney, bone, stomach, and other tissues and organs. As a result, the development of a drug that cures RA is urgently required for clinical use.

Traditional Chinese Medicine (TCM), especially herbal medicine, can be used to a great extent to improve RA treatment by utilizing the synergistic effects of herbal components and neutralizing their toxic effects in the mixture. Of the effective clinical formulae, Gui-Zhi-Shao-Yao-Zhi-Mu...
decoction, developed by Zhongjing Zhang with extensive use in RA treatments in China from the Han Dynasty, demonstrates therapeutic properties with analgesic and anti-inflammatory effects, in addition to the regulation of an antigen-driven autoimmune response, whole-body lipid metabolism, and matrix degradation in human joints [4]. Another TCM formula, the Bi-Qi capsule, commonly prescribed for RA in China, alleviates RA-induced inflammation, synovial hyperplasia, and cartilage destruction [5].

Many extensively studied natural products used for the therapy RA, such as sinomenine [6], curcumin [7], resveratrol [8], and gingerol [9], are reported to have the capability to suppress numerous proinflammatory mediators. Therefore, herbal products possessing beneficial properties may serve as potential therapeutic agents to treat RA, either alone or in combination with particular mainstream antiarthritis drugs.

The initiation of RA is not yet fully understood, but it has been confirmed that dysregulation of the immuno-inflammatory system plays a significant role in the pathophysiology of RA [10]. The aberrant production of inflammatory mediators such as TNF-α, IL-1β, IL-6, IL-4, and IL-17 secreted by a variety of immunocytes and macrophages infiltrate into the synovium of multiple joints, leading to long-term inflammation, ultimately resulting in irreversible joint and cartilage destruction [11]. Given the crucial role that proinflammatory cytokines have in the induction and maintenance of RA, regulation of these cytokines on regulatory T cells (Tregs) can be a target to strengthen immune tolerance and protect against the formation of osteoclasts [12]. Synovitis is the principal cause of joint bone erosion, closely associated with lack of control of a number of regulators that maintain osteoclast homeostasis, such as increased receptor activator of nuclear factor ?B ligand (RANKL) levels and decreased osteoprotegerin (OPG) [13, 14]. Thus, the main purpose of current treatments for RA is to reduce the immuno-inflammatory response, inhibit the development of lesions and bone damage, and protect the function of joints.

*Nigella glandulifera* seeds belong to the buttercup family Ranunculaceae. As a traditional Uighur medicine, they are widely used for hypertension, diabetes, and inflammatory diseases such as bronchitis, arthritis, and hepatitis and exhibit considerable efficacy with few side effects [15]. Contributions to the medical properties of *Nigella glandulifera* seeds are the many active constituents, of which saponins are the principal component in extracts of water, comprising 64.5% of the total. Total saponins from *Nigella glandulifera* seeds (TSNGS) have been reported to participate in providing their anti-inflammatory, analgesic, and antioxidant properties [16, 17]. We have previously reported on the potent effects of TSNGS on reducing paw swelling and inflammation in a mouse model of collagen-induced arthritis [18]. However, there still lacks evidence for the pharmacological mechanism for the therapeutic effects of TSNGS against RA. In the present study, we have investigated the therapeutic effects of TSNGS in an adjuvant-induced rheumatoid arthritis (AIA) rat model and explored the potential mechanism by which immuno-inflammatory function is recovered and bone erosion diminished.

### 2. Materials and Methods

#### 2.1. Chemical and Reagents

TSNGS was provided by the Xinjiang Institute of Materia Medica (Urumqi, China). Tripterygium glycosides (TG) were purchased from the Hunan Qianjin Xieli Pharmaceutical Co. Ltd. (Zhuozhou, China).

#### 2.2. Plant Materials and Preparation of TSNGS.

*Nigella glandulifera* seeds were collected from Hetian (Xinjiang, China) in 2017. The strain was authenticated by Prof. Jiang He, Xinjiang Institute of Materia Medica. A voucher specimen (No. NG20170830) was deposited in the Herbarium of Xinjiang Institute of Material Medica (Urumqi, China). The extraction of TSNGS has been described in our previously published report [17]. Qualitative analysis was performed using a UHPLC-Q-Exactive mass spectrometry system consisting of an Ultimate 3000 RSLC (Dionex, USA) combined with a Quadrupole-Orbitrap-HRMS (Thermo Fisher Scientific, Bremen, Germany) (Figure 1).

#### 2.3. Animals and Treatment.

Wistar specific-pathogen-free (SPF) rats (6-7 weeks old, mean body weight 180 ± 10 g, thirty males and thirty females) were provided by the Beijing Vital River Laboratory Animal Technology Co. Ltd (Beijing, China). The rats were maintained in standard laboratory conditions (21°C-25°C, 40%-60% humidity within a 12 h light/12 h dark cycle) with free access to standard rat chow and tap water, in accordance with the Experimental Animal Care and Use Committee guidelines. The Animal Care and Use Ethics Committee of the Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College approved all animal experiments (No. IMB-201908-D6).

The AIA model is a well-established chronic inflammatory model, widely used for the study of diverse human arthritis, especially rheumatoid arthritis. The AIA rat model was established in accordance with previously published literature [19]. Briefly, 50 AIA rats were injected once with 0.1 mL complete Freund’s adjuvant (CFA) (1 mg/mL; Sigma-Aldrich, Merck KGaA, Darmstadt, Germany) intradermally into the hind paw on day 1 of the experiment. Ten control rats were injected with the same volume of normal saline. The rats were randomly divided into a control group, AIA model group, AIA treatment groups, in which rats were administrated 10 mg/kg, 50 mg/kg, or 250 mg/kg TSNGS intragastrically, and AIA positive control group, which received the drug TG (9 mg/kg). There were ten rats in each group (five males and five females). All treated AIA rats were administrated TSNGS or TG dissolved in 0.5% sodium carboxymethyl cellulose (CMC-Na) by oral gavage once per day from the 3rd to the 21st day. The control group and AIA model group received 0.5% CMC-Na by gavage over the same period.

The rats were sacrificed by inducing deep anesthesia using intraperitoneal injection of 60 mg/kg pentobarbital. Blood was obtained by cardiac puncture. Serum was obtained from the blood by centrifugation at 1000 g for 15 min after which it was stored at -80°C for the assessment of inflammatory cytokines. A proportion of the blood was anticoagulated...
Figure 1: Continued.
Figure 1: Continued.
in an ethylenediamine tetraacetic acid- (EDTA-) coated anticoagulation tube at 4°C for the evaluation of Tregs.

Ankle joints and knee joints were harvested from 6 rats in each group, three males and three females, for histopathological analysis. The ankle joints, knee joints, and synovial tissues of the remaining rats were collected for Western blot (WB) analysis and quantitative polymerase chain reaction (qPCR).

2.4. Evaluation of Paw Edema, Arthritis Score, and Body Weight in AIA Rats. Paw edema, arthritis score, and body weight were recorded to evaluate the severity of the RA pathological process. Prior to CFA injection, the volume of the hind paw was measured as the baseline value. The first CFA injection was administered on day 1. The same measurements were performed on days 3, 5, 7, 9, 11, 13, 15, 17, 19, and 21 following CFA injection. The clinical paw score of the AIA model was recorded independently by two observers blinded to the grouping of each rat in accordance with previous research (0 = normal, 1 = slight swelling and redness, 2 = moderate swelling and redness, 3 = severe swelling and redness to the ankle, and 4 = extremely severe swelling and redness representing severe deformity) [20]. In addition, the weight of each rat was recorded (in grams (g)) every two days from the 3rd day.

2.5. Histochemical and Immunohistochemical Evaluation. The knee and ankle joints were harvested from rats on the 21st day after injection of CFA. The specimens were fixed in 4% paraformaldehyde for 48 hours, decalcified in buffered 10% EDTA at 4°C for 1 month, then embedded in paraffin. Tissues were serially sectioned onto standard glass slides at a thickness of 4 μm then subsequently deparaffinized and stained with hematoxylin and eosin (H&E, Servicebio, Wuhan, China). Image acquisition, morphological changes, and cellular infiltration analysis were conducted after dehydration and mounting. Notably, semiquantitative grading with five scores was used to evaluate the histopathological changes in the AIA joints (0 = insignificant changes, 1 = minimal change, 2 = mild changes, 3 = moderate changes, and 4 = marked changes).

Tissue sections were created for evaluation by immunohistochemistry and incubated with anti-forkhead box p3 (Foxp3) antibody (Servicebio) at 4°C overnight, a color reaction developed using diaminobenzidine tetrahydrochloride (DAB), and nuclei counterstained with hematoxylin in accordance with the manufacturer’s instructions. Images were acquired using an inverted microscope (Thermo Fisher Scientific, Carlsbad, CA, United States) and the ImageJ software used for qualification (National Institutes of Health, Bethesda, MD, United States).
2.7. Flow Cytometric Analysis of CD4+ CD25+ Tregs.

As follows: predenaturation at 95°C for 1 min, then 85°C for 5 sec. ChamQ SYBR Master Mix was used to perform qPCR analysis using a real-time PCR system (BIOER, Hangzhou, China) in accordance with the manufacturer’s instruction. Ten μM specific forward and reverse primers was used in the assay, as detailed in Table 1. Additionally, GAPDH was used as the internal reference. The qPCR procedure was performed in a thermal cycler as follows: 37°C for 15 min, then 95°C for 30 sec. The cell suspension was transferred into tubes and washed in phosphate-buffered saline (PBS). All stained cells were analyzed using a FACSCanto II flow cytometer (BD Biosciences) and the FlowJo software.

2.8. Enzyme-Linked Immunosorbent Assay (ELISA) Analysis.

ELISA of rat serum samples was performed to measure the expression of cytokines: TNF-α, IL-1β, IL-4, IL-6, IL-10, IL-17A, RANKL, and OPG (RayBioech, Guangzhou, China), in accordance with the manufacturer’s instructions. OD values at a wavelength of 450 nm were measured using a Spark 20 M multimode microplate reader (Tecan Group Ltd., Mannedorf, Switzerland). Concentrations were calculated from standard curves.

2.9. Western Blot Analysis.

The primary antibodies used in the present study were against the following antigens: RANKL (rabbit polyclonal antibody, dilution 1:1000, Proteintech), OPG (rabbit polyclonal antibody, dilution 1:300, Abcam, Cambridge, MA, USA), and β-actin (internal control, rabbit polyclonal antibody, dilution 1:5000, Abcam). Proteins from the knee joint were separated using SDS-PAGE then transferred to polyvinylidene difluoride membranes. The intensity of each protein was normalized using β-actin and expressed as a proportion of the control. Analysis of Western blots was performed in accordance with a previous study [21].

2.10. Statistical Analysis.

The experimental data are expressed as means ± standard error of the mean (SEM) and analyzed using the GraphPad Prism version 8.0 software (GraphPad, Inc., La Jolla, CA, United States). Arthritis scores, body weight, and paw edema were analyzed using repeated measures one-way analysis of variance (ANOVA). Other data were analyzed using ANOVA and post hoc testing or with a Student t-test. P values <0.05 were considered statistically significant.

3. Results

3.1. TSNGS Relieved RA-Like Symptoms including Paw Swelling and Clinical Score in AIA Rats.

Following subcutaneous injection of CFA in rat hind paws, compared with the control group, the volume of the hind paws increased, the inflammatory symptoms, erythema, and swelling increased significantly, relevant spontaneous activity of the rats decreased, and clinical scores were maintained at 3 to 4 points, peaking on day 3 (Figures 2(a)–2(c), P < 0.001), indicating the onset of arthritis.

During the progression of RA, the mean clinical score in the AIA group was significantly higher than that of the control group (Figure 2(a), P < 0.001). Hind paw swelling was observed to be approximately 3 mm in thickness in AIA rats (Figures 2(b) and 2(c), P < 0.001). Treatment with 10 mg/kg, 50 mg/kg, and 250 mg/kg TSNGS significantly reduced the clinical score and inhibited paw swelling in AIA rats during the period of the experiment (P < 0.01–0.001). TSNGS at 250 mg/kg displayed protective effects comparable with those of the positive drug, TG, in the rats. No statistical difference was observed in body weight among different treatment groups (Figure 2(d)).

3.2. TSNGS Improved Histological Changes in Knee and Ankle Joints in AIA Rats.

H&E staining of knee and ankle joints was conducted to evaluate inflammation and bone lesions in AIA rats. As can be observed in Figure 3, no abnormal pathological changes occurred in the knee and ankle joints of control rats. The synovial cells of the joints in the control group were

| Primer name | Primer sequence |
|-------------|-----------------|
| Tnf-F       | 5′-CCGACTCTGACCCCCATAC-3′ |
| Tnf-R       | 5′-CCCAGAGCCACAAATTCTCCT-3′ |
| Il1β-F      | 5′-CAGGATGAGGACCCAGCATC-3′ |
| Il1β-R      | 5′-GTGCTCATCTACCCACGATC-3′ |
| Il6-F       | 5′-TGCTCTTCTGAGGCTGATGT-3′ |
| Il6-R       | 5′-TGTCCTTGTGGGTGATCTAC-3′ |
| Il17α-F     | 5′-GCTCTGAGAGGACCTGAG-3′ |
| Il17α-R     | 5′-GCGGACATAGGAAAGGGAAC-3′ |
| Il10-F      | 5′-GACAAAGGGTGCTCAAGGCGCA-3′ |
| Il10-R      | 5′-CATGTTGCTGCTTCGTCATC-3′ |
| Gapdh-F     | 5′-AGTGCCAAGCTCGTCTCATA-3′ |
| Gapdh-R     | 5′-AGAAAGGACGCGCGCTGAA-3′ |

F: forward; R: reverse.
smooth and continuous in morphology. Conversely, sections of AIA rats exhibited markedly severe synovitis, characterized by synovial cell proliferation and inflammatory cell infiltration into the joint cavity. The erosion of bone and cartilage and formation of pannus and small blood vessels was evident, consistent with increased synovial hyperplasia and inflammation (all $P < 0.001$). These pathological symptoms were mitigated to varying degrees after treatment with 10 mg/kg, 50 mg/kg, and 250 mg/kg TSNGS ($P < 0.05-0.001$). In particular, at a dose of 250 mg/kg, synovial cell proliferation, cartilage erosion, and infiltration of inflammatory cells were clearly attenuated and represented a better therapeutic effect than TG.

3.3. TSNGS Downregulated the Expression of Cytokines Mediated by Inflammation in AIA Rats.

ELISA and qPCR were performed to detect proinflammatory factors, including TNF-$\alpha$, IL-1$\beta$, IL-6, IL-17A, IFN-$\gamma$, and anti-inflammatory factors IL-10 and IL-4 in rat serum and synovial tissue. The mRNA expression levels in the synovial tissue and/or serum concentration of TNF-$\alpha$, IL-1$\beta$, IL-6, IL-17A, and IFN-$\gamma$ in AIA rats were significantly higher than in the control (Figures 4(a)–4(d) and 4(g), $P < 0.01-0.001$). mRNA and protein expression levels of IL-10 and IL-4 declined in the synovial tissue and/or serum in AIA rats (Figures 4(e) and 4(f), $P < 0.05-0.001$). Treatment with TSNGS significantly inhibited inflammation by downregulation of TNF-$\alpha$, IL-1$\beta$, IL-6, IFN-$\gamma$, and IL-17A and upregulation of IL-10 and IL-4 in the serum and synovial tissues ($P < 0.05-0.001$). A dosage of 250 mg/kg TSNGS displayed anti-inflammatory effects similar to those of TG.

3.4. TSNGS Increased the Proportion of CD4$^+$ CD25$^+$ Tregs in Peripheral Blood and the Expression of Foxp3 in Knee Joints in AIA Rats.

CD4$^+$ CD25$^+$ Tregs are an essential subpopulation of T cells, positively expressing the transcription factor Foxp3 and yielding immunosuppressive group, CD4$^+$ CD25$^+$ Tregs maintain immunologic self-tolerance and negatively modulate the occurrence and development of immune disorders [22]. The percentage of CD4$^+$ CD25$^+$ Tregs decreased significantly in peripheral blood (Figures 5(a) and 5(b), $P < 0.05$), accompanied by decreased levels of Foxp3 in the knee joint of AIA rats (Figures 5(c) and 5(d), $P < 0.01$). Treatment with TSNGS resulted in a significant increase in the percentage of CD4$^+$ CD25$^+$ Tregs and upregulated expression of Foxp3 in AIA.

**Figure 2**: TSNGS relieved RA-like symptoms in AIA rats. (a) TSNGS significantly decreased clinical scores in AIA rats compared with model rats. (b) TSNGS markedly mitigated the swelling of the hind paws in AIA rats compared with model rats. (c) Representative images of swollen hind paws of rats in each group. (d) Rat body weights were not significantly different in each group. Results are presented as means ± SEM, $n = 10$. ***$P < 0.001$ vs. sham, **$P < 0.01$, ***$P < 0.001$ vs. model.
rats ($P < 0.05$-$0.001$), suggesting that the promotion of a CD4$^+$ CD25$^+$ Treg response contributed to the immunoinflammatory suppressive effect of TSNGS.

3.5. TSNGS Decreased Bone Erosion by Increasing the OPG/RANKL Ratio in AIA Rats. To investigate the potential mechanism of the anti-RA effects of TSNGS on bone erosion, the OPG/RANKL ratio was measured to signify the degree of osteoclastogenesis. As shown in Figure 6, the level of OPG decreased significantly, and RANKL increased both in serum and in the knee joint, resulting in a reduced OPG/RANKL ratio compared with the control group (Figures 6(a)–6(e), $P < 0.05$-$0.001$). Treatment with TSNGS resulted in a noticeable decrease in the levels of RANKL and an apparent increase in OPG levels, resulting in an increased OPG/RANKL ratio in AIA rats ($P < 0.05$-$0.001$). Furthermore, the ameliorative action of TSNGS on the OPG/RANKL ratio indicated that bone erosion was
Figure 4: Continued.
OPG/RANKL pathways. Therefore, these Tregs, and bone-protection due to upregulation of ...

There are two major contributions the present study provides to the science of TSNGS action. To our knowledge, this is the first study to establish the beneficial effects of TSNGS against RA injury. These results indicate that TSNGS might reduce bone erosion by restoring the abnormal OPG/RANKL axis against RA injury.

4. Discussion

There are two major contributions the present study provides to the science of TSNGS action. To our knowledge, this is the first study to establish the beneficial effects of TSNGS against RA by alleviating inflammation, enhancing immunosuppressive function, and decreasing bone erosion. Second, following RA-associated perturbation, TSNGS was found to interfere with the counter-balancing of systemic and local inflammatory cytokines, elevation of the proportion of CD4+ CD25+ Tregs, and bone-protection due to upregulation of OPG/RANKL pathways. Therefore, these findings provide novel evidence and insights into TSNGS that clarify its therapeutic effects and possible mechanisms against RA injury.

CFA-induced RA in rats is a stable, reliable, and reproducible model of short experimental duration and similar clinical characteristics to that of human RA regarding inflammatory cell infiltration, synovitis, synovial hyperplasia, and cartilage degradation. Thus, it is widely used in the preclinical pharmacological evaluation of anti-RA drugs [23, 24]. TG, selected as a positive control drug in the present study, is routinely used for RA treatment due to its proven efficacy, relative safety, and cost-effectiveness [25]. Nevertheless, similar to DMARDs, TG has side effects, causing liver injury, gastrointestinal discomfort, and gonad toxicity [26] and therefore should be recommended only for use in patients without reproductive needs. Attention has thus focused on plant-derived products with multifactorial efficacy and relatively few side effects as potential candidate drugs for RA treatment.

Following adjuvant injection, arthritis-related symptoms were gradually exacerbated in AIA rats, in which paw swelling, clinical score, histopathological parameters, and body weight were used to assess the severity of arthritis and the beneficial effects of TSNGS. No statistical difference was observed in the body weight of AIA rats, implying that TSNGS did not produce systemic toxicity. Subsequent results demonstrated a powerful inhibition of TSNGS on paw swelling and clinical score, as well as histopathological parameters. Significantly, the effects of 250 mg/kg TSNGS on the volume of hind paws, clinical score, and histopathological parameters suggested a therapeutic potency similar or even better than that of TG, indicating that TSNGS represents a new potential therapy for the treatment of RA.

Critical proinflammatory cytokines TNF-α, IL-1β, IL-6, IL-17A, and others derived from activated macrophages and synovial fibroblasts are primary factors that cause inflammation in RA [27–30], not only in joints and synovial fluid but also in serum [31]. TNF-α activates the cytokine cascade in RA via stimulation of proinflammatory cytokines and inhibition of anti-inflammatory cytokines such as IL-4 and IL-10 [32]. Although five TNF inhibitors (etanercept, infliximab, adalimumab, certolizumab, and golimumab) and one IL-6 inhibitor (tocilizumab) are available for the routine clinical treatment of RA [33, 34], more than a third of RA patients do not respond to this treatment [35, 36]. Therefore, those partial responders and nonresponders to cytokine inhibitors are in great need of substitutable, effective anti-inflammatory drugs. In the present study, observation of aberrant levels of the proinflammatory cytokines TNF-α, IL-1β, IL-6, and IL-17A, besides anti-inflammatory cytokines IL-4 and IL-10 in the serum and synovial tissues of rats, indicates that the AIA model of RA was successfully established. It is evident that administration of TSNGS downregulated the expression of TNF-α, IL-1β, IL-6, and IL-17A and upregulated IL-4 and IL-10 expression, displaying a useful

Figure 4: TSNGS downregulated the level of cytokines mediated by inflammation in AIA rats. The level of TNF-α (a), IL-1β (b), IL-6 (c), IL-17A (d), IL-10 (e), IL-4 (f), and IFN-γ (g) in rat serum or synovial tissue was measured by ELISA or qPCR. Results are presented as means ± SEM, n = 4. *P < 0.05, **P < 0.01, ***P < 0.001 vs. sham, *P < 0.05, **P < 0.01, ***P < 0.001 vs. model.
improvement of the inflammatory environment. Thus, these results confirm the effectiveness of TSNGS in RA therapy, illustrated by potent inhibition of the inflammatory response.

Considering that CD4+ T cells regulate the inflammatory environment in RA through a variety of subsets, we investigated the regulation by TSNGS of the diverse population of CD4 T cells in AIA rats. Naïve CD4+ T cells may differentiate into T helper cells (Th) and Tregs, characterized by cytokines IL-4 and IL-17 [37]. Tregs play a critical role in peripheral immune tolerance and inflammatory homeostasis regulators, of which the Foxp3 expression is defined as an inherent hallmark [38]. Studies have demonstrated that an imbalance in IL-17-producing Th17 and Tregs affects the pro- or anti-inflammatory T cell-mediated immune response and makes a considerable contribution to the pathological direction of RA [39]. A previous study demonstrated that IL-1β, IL-6, and TGF-β promotes the differentiation of naive T cells into Th17 cells [40] and in turn suppresses Treg differentiation, leading to homeostasis disorders. IL-17 generated by Th17 affects a variety of immune cells that activates inflammation and the differentiation of osteoclasts by induction of RANKL in the synovium [41]. Therefore, the balance between Treg and Th17 cell differentiation is defined by the patterns of cytokine production and function towards pro- or anti-

**Figure 5**: TSNGS increased the proportion of CD4+ CD25+ Tregs in peripheral blood and the expression of Foxp3 in knee joints in AIA rats. (a) Representative images of CD4+ CD25+ Tregs in peripheral blood detected by flow cytometry. (b) Quantification of the percentage of CD4+ CD25+ Tregs in peripheral blood. (c) Representative immunohistochemical staining images of Foxp3 protein. (d) Percentage of positive cells expressing Foxp3. Results represent means ± SEM, n = 4. *P < 0.05, **P < 0.01 vs. sham, ***P < 0.001 vs. model.
inflammation. In the present study, treatment with TSNGS caused high expression of CD4+ CD25+ Tregs combined with upregulated Foxp3 expression in AIA rats, displaying excellent immune amelioration by maintaining the frequency of Tregs and the patterns of cytokine production. Therefore, an increase in the proportion of CD4+ CD25+ Tregs resulting

**Figure 6:** TSNGS decreased bone erosion by increasing the OPG/RANKL ratio in AIA rats. Levels of OPG (a) and RANKL (b) in rat serum were measured using ELISA. (c) Ratio of OPG/RANKL expression in rat serum. (d) Representative images of OPG and RANKL in the various groups. (e) Quantitative WB analysis. Results represent means ± SEM. n = 4, #P < 0.05, ##P < 0.01, ###P < 0.001 vs. sham, *P < 0.05, **P < 0.01, ***P < 0.001 vs. model.
from TSNGS treatment might be a mechanism of inflammatory inhibition in RA.

Osteoclast-mediated bone destruction that occurs through the abnormal OPG/RANKL axis plays a crucial role in RA [42, 43]. In the present study, TSNGS reduced damage to the articular cartilage and bone in AIA rats. Thus, the molecular balance between OPG and RANKL that determines the proliferation and activity of osteoclasts and osteoblasts was investigated. OPG acts as an inhibitor of RANKL, a critical factor in the formation of osteoclasts by activating osteoclasts and bone resorption. OPG reduces the interaction between RANKL and RANK and is produced by a number of cell types, including T cells, macrophages, and synovial fibroblasts in RA, thus inhibiting the formation of osteoclasts. Therefore, restoration of the OPG/RANKL ratio plays a vital role in reducing bone damage in RA. Notably, TSNGS reduced the level of RANKL and increased the level of OPG both in serum and the knee joints of AIA rats, thus raising the ratio of OPG/RANKL and so suppressing inflammation-induced osteoclastogenesis. These observations suggest that bone protection resulting from TSNGS might be associated with upregulation of OPG/RANKL.

Nevertheless, the present study has some limitations. Firstly, it is necessary to establish a greater number of RA models both in vivo and in vitro to clarify the specific molecular mechanism of the therapeutic effects of TSNGS and to analyze the key pathological genes and proteins in RA. Therefore, the extraction process or composition of TSNGS should be enhanced in the future to exert a more significant anti-RA effect in patients.

5. Conclusions

In conclusion, the present study has demonstrated that treatment with TSNGS inhibits arthritis caused by AIA, suppressing a local and systemic inflammatory response and bone erosion. The underlying mechanism of the action of TSNGS may be associated with restoration of the balance of pro- and anti-inflammatory cytokines, elevation of the frequency of CD4+ CD25+ Tregs, and reduction of the bone injury via the OPG/RANKL pathway (Figure 7).

Data Availability

The data used to support the findings of this study are available from the corresponding authors upon request.

Conflicts of Interest

The authors declare that they have no conflict of interest.

Authors’ Contributions

Zeng L carried out the in vivo experiments, analyzed results, and wrote the manuscript. Li C and Chen Y prepared TSNGS and conducted the profile analysis. Jiang H performed the inflammatory cytokine measurement and prepared the figures. Li Z helped design experiments and reviewed the manuscript. Liu R and Xu F designed the study and experiments, interpreted results, and revised the manuscript. All authors have read and approved the final manuscript.

Acknowledgments

This work was supported by the National Natural Science Foundation of China (Nos. 81660655 and U1803281) and the Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences (2018RC350013).
References

[1] M. Cross, E. Smith, D. Hoy et al., “The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study,” *Annals of the Rheumatic Diseases*, vol. 73, no. 7, pp. 1316–1322, 2014.

[2] J. Charles, H. Britt, and Y. Pan, “Rheumatoid arthritis,” *Australian Family Physician*, vol. 42, no. 11, p. 765, 2013.

[3] S. Larice, A. Ghiggia, M. Di Tella et al., “Pain appraisal and quality of life in 108 outpatients with rheumatoid arthritis,” *Scandinavian Journal of Psychology*, vol. 61, no. 2, pp. 271–280, 2019.

[4] M. C. Huang, F. T. Pai, C. C. Lin et al., “Characteristics of traditional Chinese medicine use in patients with rheumatoid arthritis in Taiwan: a nationwide population-based study,” *Journal of Ethnopharmacology*, vol. 176, pp. 9–16, 2015.

[5] K. Wang, D. Zhang, Y. Liu et al., “Traditional Chinese medicine formula Bi-Qi capsule alleviates rheumatoid arthritis-induced inflammation, synovial hyperplasia, and cartilage destruction in rats,” *Arthritis Research & Therapy*, vol. 20, no. 1, p. 43, 2018.

[6] W. Liu, Y. Zhang, W. Zhu et al., “Sinomenine inhibits the progression of rheumatoid arthritis by regulating the secretion of inflammatory cytokines and monocyte/macrophage subsets,” *Frontiers in Immunology*, vol. 9, p. 2228, 2018.

[7] Q. Dai, D. Zhou, L. Xu, and X. Song, “Curcumin alleviates rheumatoid arthritis-induced inflammation and synovial hyperplasia by targeting mTOR pathway in rats,” *Drug Design, Development and Therapy*, vol. Volume 12, pp. 4095–4105, 2018.

[8] G. Yang, C. C. Chang, Y. Yang et al., “Rosveratrol alleviates rheumatoid arthritis via reducing ROS and inflammation, inhibiting MAPK signaling pathways, and suppressing angiogenesis,” *Journal of Agricultural and Food Chemistry*, vol. 66, no. 49, pp. 12953–12960, 2018.

[9] R. B. Semwal, D. K. Semwal, S. Combrinck, and A. M. Viljoen, “Gingerols and shogaols: important nutraceutical principles from ginger,” *Phytochemistry*, vol. 117, pp. 554–568, 2015.

[10] I. B. McNinnes and G. Schett, “Cytokines in the pathogenesis of rheumatoid arthritis,” *Nature Reviews. Immunology*, vol. 7, no. 6, pp. 429–442, 2007.

[11] L. A. Ridgley, A. E. Anderson, and A. G. Pratt, “What are the dominant cytokines in early rheumatoid arthritis?” *Current Opinion in Rheumatology*, vol. 30, no. 2, pp. 207–214, 2018.

[12] Q. Yu, M. Xu, F. Yu, and Y. Jin, “CD4(+)CD25(+) regulatory T cells as a therapeutic target in rheumatoid arthritis,” *Central-European Journal of Immunology*, vol. 39, no. 1, pp. 100–103, 2014.

[13] G. Schett and E. Gravallese, “Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment,” *Nature Reviews Rheumatology*, vol. 8, no. 11, pp. 656–664, 2012.

[14] J. Z. Zeng, L. F. Ma, H. Meng, H. M. Yu, Y. K. Zhang, and A. Guo, “(5R)-5-hydroxytriptolide (LLDT-8) prevents collagen-induced arthritis through OPG/RANK/RANKL signaling in a rat model of rheumatoid arthritis,” *Experimental and Therapeutic Medicine*, vol. 12, no. 5, pp. 3101–3106, 2016.

[15] A. Aikemu, X. Xiaerfuding, C. Shiwenhu, M. Abudureyimu, and D. Mainaiyiyiming, “Immunomodulatory and anti-tumor effects of Nigella glandulifera freyn and sint seeds on ehrlch ascites carcinoma in mouse model,” *Pharmacognosy Magazine*, vol. 9, no. 35, pp. 187–191, 2013.

[16] Z. Tian, Y. M. Liu, S. B. Chen et al., “Cytotoxicity of two triterpenoids from Nigella glandulifera,” *Molecules*, vol. 11, no. 9, pp. 693–699, 2006.

[17] J. Zhao, F. Xu, H. Huang et al., “Evaluation on anti-inflammatory, analgesic, antimicrobial, and antioxidant potential of total saponins from Nigella glandulifera seeds,” *Evidence-Based Complementary and Alternative Medicine*, vol. 2013, Article ID 827230, 8 pages, 2013.

[18] L. L. Wang, Y. Z. Shi, and F. Xu, “Evaluation on arthritis of total saponins from Nigella glandulifera seeds,” *Pharmacology and Clinics of Chinese Materia Medica*, vol. 30, no. 3, pp. 78–82, 2014.

[19] Z. C. Zhang, S. J. Zhang, B. Jin et al., “Ciclamist ameliorates adjuvant-induced arthritis in a rat model,” *BioMed Research International*, vol. 2015, Article ID 786104, 11 pages, 2015.

[20] E. Perilli, M. Cantley, V. Marino et al., “Quantifying not only bone loss, but also soft tissue swelling, in a murine inflammatory arthritis model using micro-computed tomography,” *Scandinavian Journal of Immunology*, vol. 81, no. 2, pp. 142–150, 2015.

[21] H. Jiang, L. Zeng, X. Dong et al., “Tiliannin extracted from Dracocephalum moldavica L induces intrinsic apoptosis and drives inflammatory microenvironment response on pharyngeal squamous carcinoma cells via regulating TLR4 signaling pathways,” *Frontiers in Pharmacology*, vol. 11, p. 205, 2020.

[22] S. Sakaguchi, M. Ono, R. Setoguchi et al., “Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease,” *Immunological Reviews*, vol. 212, no. 1, pp. 8–27, 2006.

[23] K. J. Gou, R. Zeng, X. D. Ren et al., “Anti-rheumatoid arthritis effects in adjuvant-induced arthritis in rats and molecular docking studies of Polygonum orientale L. extracts,” *Immunology Letters*, vol. 201, pp. 59–69, 2018.

[24] P. Jia, G. Chen, W. Y. Qin, Y. Zhong, J. Yang, and X. F. Rong, “Xitong Wan attenuates inflammation development through inhibiting the activation of nuclear factor-κB in rats with adjuvant-induced arthritis,” *Ethnopharmacology*, vol. 193, pp. 266–271, 2016.

[25] W. Zheng, Y. Mei, C. Chen, L. Cai, and H. Chen, “The effectiveness and safety of Tripterygium wilfordii glycosides combined with disease-modifying anti-rheumatic drugs in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of 40 randomized controlled trials,” *Phytotherapy Research*, 2020.

[26] J. Luo, W. J. Song, Y. Xu, G. Y. Chen, Q. Hu, and Q. W. Tao, “Benefits and safety of tripterygium glycosides and total glucosides of paeony for rheumatoid arthritis: an overview of systematic reviews,” *Chinese Journal of Integrative Medicine*, vol. 25, no. 9, pp. 696–703, 2019.

[27] F. M. Brennan and I. B. McNinnes, “Evidence that cytokines play a role in rheumatoid arthritis,” *The Journal of Clinical Investigation*, vol. 118, no. 11, pp. 3537–3545, 2008.

[28] S. Siebert, A. Tsoukas, J. Robertson, and I. McInnes, “Cytokines as therapeutic targets in rheumatoid arthritis and other inflammatory diseases,” *Pharmacological Reviews*, vol. 67, no. 2, pp. 280–309, 2015.

[29] T. Bahktiari, S. Azarian, A. Ghaderi, A. Ahmadiane, and A. Mirshafiey, “Effect of gularic acid (G2013), as a new anti-inflammatory drug on gene expression of pro-inflammatory and anti-inflammatory cytokines and their transcription factors in rheumatoid arthritis patients,” *Iranian
[30] X. Dong, Z. Zheng, P. Lin et al., “ACPAs promote IL-1β production in rheumatoid arthritis by activating the NLRP3 inflammasome,” Cellular & Molecular Immunology, vol. 17, no. 3, pp. 261–271, 2020.

[31] H. I. Chiang, J. R. Li, C. C. Liu et al., “An association of gut microbiota with different phenotypes in Chinese patients with rheumatoid arthritis,” Journal of clinical medicine, vol. 8, no. 11, p. 1770, 2019.

[32] E. H. Choy and G. S. Panayi, “Cytokine pathways and joint inflammation in rheumatoid arthritis,” The New England Journal of Medicine, vol. 344, no. 12, pp. 907–916, 2001.

[33] H. Kameda, “TNF inhibitors,” Nihon Rinsho, vol. 74, no. 6, pp. 957–962, 2016.

[34] G. W. Kim, N. R. Lee, R. H. Pi et al., “IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future,” Archives of Pharmacal Research, vol. 38, no. 5, pp. 575–584, 2015.

[35] R. Prajapati, D. Plant, and A. Barton, “Genetic and genomic predictors of anti-TNF response,” Pharmacogenomics, vol. 12, no. 11, pp. 1571–1585, 2011.

[36] T. M. Thomson, R. M. Lescarbeau, D. A. Drubin et al., “Blood-based identification of non-responders to anti-TNF therapy in rheumatoid arthritis,” BMC medical genomics, vol. 8, no. 26, 2015.

[37] T. M. Scharton and P. Scott, “Natural killer cells are a source of interferon gamma that drives differentiation of CD4+ T cell subsets and induces early resistance to Leishmania major in mice,” The Journal of Experimental Medicine, vol. 178, no. 2, pp. 567–577, 1993.

[38] B. Min, M. Prout, J. Hu-Li et al., “Basophils produce IL-4 and accumulate in tissues after infection with a Th2-inducing parasite,” The Journal of experimental medicine, vol. 200, no. 4, pp. 507–517, 2004.

[39] C. Scheinecker, L. Göschl, and M. Bonelli, “Treg cells in health and autoimmune diseases: new insights from single cell analysis,” Journal of Autoimmunity, vol. 110, article 102376, 2020.

[40] T. Kmioleck, E. Rzeszotarska, A. Wajda et al., “The interplay between transcriptional factors and microRNAs as an important factor for Th17/Treg balance in RA patients,” International journal of molecular sciences, vol. 21, no. 19, article 7169, 2020.

[41] K. Sato, A. Suematsu, K. Okamoto et al., “Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction,” The Journal of experimental medicine, vol. 203, no. 12, pp. 2673–2682, 2006.

[42] S. Remuzgo-Martínez, F. Genre, R. López-Mejías et al., “Expression of osteoprotegerin and its ligands, RANKL and TRAIL, in rheumatoid arthritis,” Scientific reports, vol. 6, article 29731, 2016.

[43] P. Geusens, “The role of RANK ligand/osteoprotegerin in rheumatoid arthritis,” Therapeutic advances in musculoskeletal disease, vol. 4, no. 4, pp. 225–233, 2012.